| Identification | Back Directory | [Name]
3-[2-[(1R,4aβ)-2-Methylene-5α-(hydroxymethyl)-5,8aα-dimethyl-6α-hydroxydecalin-1α-yl]ethyl]-2,5-dihydrofuran-2-one | [CAS]
4176-97-0 | [Synonyms]
AD 04130-4
Andrographolide Impurity 8
3-[2-[(1R,4aβ)-2-Methylene-5α-(hydroxymethyl)-5,8aα-dimethyl-6α-hydroxydecalin-1α-yl]ethyl]-2,5-dihydrofuran-2-one
3-[2-[(1R,4aβ)-Decahydro-6α-hydroxy-5α-hydroxymethyl-5,8aα-dimethyl-2-methylenenaphthalen-1α-yl]ethyl]furan-2(5H)-one
3-{2-[(1R,4aS,5R,6R,8aS)-6-Hydroxy-5-(hydroxymethyl)-5,8a-dimethy l-2-methylenedecahydro-1-naphthalenyl]ethyl}-2(5H)-furanone
3-[2-[(1R,4aS,5R,6R,8aS)-Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethyl]-2(5H)-furanone
2(5H)-Furanone,3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethyl]- | [EINECS(EC#)]
2017-001-1 | [Molecular Formula]
C20H30O4 | [MDL Number]
MFCD01861504 | [MOL File]
4176-97-0.mol | [Molecular Weight]
334.45 |
| Chemical Properties | Back Directory | [Melting point ]
176-178℃ | [Boiling point ]
509.5±50.0 °C(Predicted) | [density ]
1.15 | [storage temp. ]
Store at -20°C | [solubility ]
Acetonitrile: soluble | [form ]
A solid | [pka]
14.89±0.70(Predicted) | [color ]
White to off-white | [InChI]
InChI=1S/C20H30O4/c1-13-4-7-16-19(2,10-8-17(22)20(16,3)12-21)15(13)6-5-14-9-11-24-18(14)23/h9,15-17,21-22H,1,4-8,10-12H2,2-3H3/t15-,16+,17-,19+,20+/m1/s1 | [InChIKey]
GVRNTWSGBWPJGS-YSDSKTICSA-N | [SMILES]
O1CC=C(CC[C@H]2[C@@]3(C)[C@@]([H])([C@@](CO)(C)[C@H](O)CC3)CCC2=C)C1=O |
| Hazard Information | Back Directory | [Chemical Properties]
White powder, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from Andrographis paniculata (Burm. f.) Nees. | [Uses]
14-Deoxyandrographolide is an Ayurvedic herb Kalmegh (Andrographis paniculata) that is used to fight against respiratory viral infections. | [in vivo]
14-Deoxyandrographolide (40 mg/kg, intraperitoneal injection, single dose) makes rat liver cells resistant to apoptosis induced by TNF-α by downregulating the formation of death-inducing signaling complex. It enhances the activity of microsomal Ca-ATPase and increases calcium ion influx into the microsomal lumen through the NO/cGMP pathway, which in turn promotes the release of TNFRSF1A[2]. | Animal Model: | Male Sprague-Dawley rats[2] | | Dosage: | 40 mg/kg; single dose | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Reduced ALT elevation caused by TNF-α/ActD, reduced the number of hepatocyte apoptosis, and reduced the amount of TNF-α retained in the liver. |
| [IC 50]
Caspase 3 | [storage]
Store at -20°C |
|
|